Rheumatology and Orthopedics· Topic 17.9 Non-inflammatory and heritable musculoskeletal disorders· 17.9.2

Marfan syndrome

Marfan syndrome is an autosomal dominant connective tissue disorder from FBN1 (fibrillin-1) mutations, with skeletal, ocular, and cardiovascular features. The cardiovascular risk drives prognosis: aortic root dilation predisposing to dissection and rupture, managed with beta-blockers or ARBs, activity restriction, surveillance imaging, and prophylactic aortic surgery.

5 min read1 practice questions7 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Definition: Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the FBN1 gene encoding fibrillin-1, affecting the skeletal, ocular, and cardiovascular systems.

  • Epidemiology

    An uncommon inherited disorder, autosomal dominant with variable expression.

  • Risk factors

    FBN1 mutation and family history (autosomal dominant inheritance).

  • Pathophysiology

    Fibrillin-1 deficiency: abnormal microfibrils weaken connective tissue and dysregulate TGF-beta signaling.

  • Clinical features

    Skeletal: tall stature, long limbs, arachnodactyly, pectus deformity, scoliosis, and joint hypermobility.

  • Differential diagnosis

    Loeys-Dietz syndrome: aggressive aortopathy with arterial tortuosity, hypertelorism, and bifid uvula or cleft palate, distinguished from Marfan by TGFBR1/2 mutations and the absence of ectopia lentis.

  • Diagnosis

    Establish with the Ghent criteria integrating aortic root dilation, ectopia lentis, FBN1 mutation, and a systemic score: the diagnostic basis is the revised Ghent nosology, combining aortic root…

  • Management

    First-line, slow aortic growth and restrict high-risk activity: a beta-blocker (for example atenolol or metoprolol 50 to 100 mg PO daily) and/or an ARB (losartan 50 to 100 mg PO daily) to reduce…

  • Complications

    Aortic dissection and rupture (the leading cause of death).

  • Prognosis

    Markedly improved by surveillance, medical therapy, and prophylactic surgery, approaching near-normal life expectancy in treated patients.

  • Prevention

    Beta-blocker and/or ARB therapy to slow aortic dilation.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.